Embecta Corp. EMBC Pen Needles — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Embecta Corp. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Embecta Corp.'s pen needles — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Embecta Corp.'s pen needles — revenue?
- Embecta Corp. (EMBC) reported pen needles — revenue of $154.7M in Q1 2026.
- How has Embecta Corp.'s pen needles — revenue changed year-over-year?
- Embecta Corp.'s pen needles — revenue decreased by 17.8% year-over-year, from $188.3M to $154.7M.
- What is the long-term trend for Embecta Corp.'s pen needles — revenue?
- Over 3 years (2022 to 2025), Embecta Corp.'s pen needles — revenue has grown at a -1.7% compound annual growth rate (CAGR), from $824.6M to $784.1M.
- What does pen needles — revenue mean?
- This metric represents the total gross revenue generated from the sale of pen needle products within the company's medical technology portfolio. It serves as a key indicator of market demand and adoption rates for the company's core diabetes care delivery solutions. Tracking this revenue stream helps investors assess the competitive positioning and lifecycle maturity of the company's primary product offerings.